Prominent Canadian researcher in Denmark: Why I left a top job in California
Foundations invest DKK 280 million in biomedical company
Management — NMD Pharma
NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
Management — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Biopeople Newsletter January 2020 - Biopeople
NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma - PIR International
NMD Pharma - Inkef capital
News — NMD Pharma
